Bernardo Stefanini
Du Cane Road
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 13, 2026
Is the hyper-defense of current patients in clinical research reducing the expectations for the cure of future patients? The case of investigator-initiated imaging and treatment studies becoming no longer sustainable.
Journal: Ultraschall in der Medizin (Stuttgart, Germany : 1980)
Published: June 10, 2026
Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: January 16, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.
Journal: Journal of general internal medicine
Published: November 19, 2025
Reproducibility of segmentation and radiomic features in contrast-enhanced CT images of early, intermediate and advanced HCC patients: a multicenter study.
Journal: European journal of radiology
Published: November 13, 2025
Performance of CEUS LI-RADS v2017 major feature combinations: individual patient data meta-analysis.
Performance of CEUS LI-RADS v2017 major feature combinations: individual patient data meta-analysis.
Journal: Abdominal radiology (New York)
Published: November 04, 2025
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: September 24, 2025
IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.
Journal: JHEP reports : innovation in hepatology
Published: September 15, 2025
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.
Journal: Alimentary pharmacology & therapeutics
Published: September 10, 2025
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Last Updated: 09/26/2026